Nursing care
Pharmacokinetics, explained for the bedside and the exam
Written and reviewed by Dana Whitfield, RN, MSN · 5 min read · Updated September 2026
Short answer
Pharmacokinetics describes what the body does to a drug: absorption, distribution, metabolism, and excretion. For nurses, the clinical weight falls on metabolism and excretion, because a failing liver or kidney stops clearing a drug at the expected rate, and a standard dose that was safe on admission can accumulate to toxic levels days later without any change in the prescription.
Defining it precisely
Pharmacokinetics is the study of drug movement through the body across four processes: absorption (how the drug gets into the bloodstream), distribution (how it spreads to tissues and organs), metabolism (how the body chemically alters it, overwhelmingly in the liver via the cytochrome P450 enzyme system), and excretion (how it leaves the body, overwhelmingly via the kidneys, with some drugs cleared through bile, lungs, or sweat).
It is distinct from pharmacodynamics, which asks what the drug does to the body once it's there — receptor binding, mechanism of action, the dose-response relationship. Pharmacokinetics answers 'how much drug is where, and for how long', which is why lab values like creatinine clearance and liver function tests are pharmacokinetic data, not incidental background information, when you're assessing whether a dose is still appropriate.
The exceptions that matter
The textbook version of pharmacokinetics assumes normal organ function, and that assumption breaks constantly in real patients. Hepatic impairment slows metabolism, so drugs that rely on liver enzymes to become inactive — many benzodiazepines, opioids, and anticoagulants among them — stay active longer and accumulate with repeated standard dosing. Renal impairment does the same for drugs cleared unchanged or as active metabolites by the kidney; digoxin, many antibiotics, and metformin are the classic examples where a reduced glomerular filtration rate demands a lower dose or longer interval, not the standard one.
Age changes both ends of the pathway: reduced hepatic blood flow and enzyme activity in older adults slows metabolism, while age-related decline in renal function slows excretion, so the same population is vulnerable on two fronts at once. Protein-binding matters too — a drug that is highly protein-bound behaves very differently in a patient with low albumin, because more of the drug circulates free and pharmacologically active than the standard dose was calculated for.
Using it to prioritise
When you're assessing a patient on multiple medications, pharmacokinetics tells you where to look for trouble before it becomes visible as a symptom. A patient with rising creatinine on a renally-cleared drug is accumulating that drug in real time, even though the dose on the MAR hasn't changed — this is a reason to hold a dose and notify the prescriber, not to wait for overt toxicity.
It also explains why a drug level or a clinical toxicity sign can appear well after a dose change or after a new nephrotoxic drug is added, rather than immediately. Vancomycin trough levels, digoxin levels, and lithium levels are all pharmacokinetic monitoring tools for exactly this reason: they catch accumulation before it becomes a crisis. Prioritise reviewing renal and hepatic function whenever a patient's clinical picture doesn't match the dose they're supposedly tolerating.
Traps in exam wording
Exam items often describe a patient with abnormal liver or kidney labs and then ask which medication effect to monitor for — the trap is assuming the drug's usual side-effect profile applies unchanged. The correct reasoning path is: identify the organ that's impaired, identify whether this drug is metabolised or excreted through that organ, and conclude that toxicity, not simple lack of effect, is the risk.
Watch for questions that give you a normal dose and a normal administration technique but an abnormal lab value elsewhere in the stem — the abnormal lab is the answer, not a distractor. Also watch for wording that conflates metabolism and excretion; a question about a hepatically metabolised drug in a patient with renal failure is testing whether you know which organ actually matters for that specific drug, not whether any organ dysfunction is present.
Examples from practice
A patient with cirrhosis is prescribed a standard opioid dose for post-operative pain. Reduced hepatic metabolism means the drug and its active metabolites persist longer than expected, so this patient needs closer sedation and respiratory monitoring at the same dose that would be routine for a patient with a healthy liver, and often needs the dose itself reduced or the interval extended.
A patient with an eGFR that's dropped from 90 to 35 over a hospital admission is still receiving their home dose of a renally-cleared antibiotic. Without a dose adjustment, the drug accumulates toward toxic levels over the following days even though nothing on the order has changed — this is the scenario pharmacokinetic monitoring exists to catch before it becomes ototoxicity or nephrotoxicity.
Summary
Pharmacokinetics is absorption, distribution, metabolism, and excretion, and for nursing practice the two that matter most are metabolism and excretion, because that's where organ failure turns a correct prescription into an accumulating overdose. The liver and kidneys are the two points of failure to check whenever a drug isn't behaving the way the textbook says it should.
Treat renal and hepatic function as pharmacokinetic vital signs for any patient on multiple medications, particularly older adults and anyone with acute organ injury. A dose that was right on day one can be wrong by day four with no change to the prescription at all, and catching that shift is a nursing assessment, not solely a pharmacy one.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
What's the difference between pharmacokinetics and pharmacodynamics?
Pharmacokinetics is what the body does to the drug — absorption, distribution, metabolism, excretion. Pharmacodynamics is what the drug does to the body — its mechanism of action and dose-response relationship. Nurses use pharmacokinetics to judge whether a dose is still appropriate given organ function.
Why do older adults need closer monitoring on standard drug doses?
Ageing reduces both hepatic metabolism and renal excretion, so the same standard dose clears more slowly on both ends of the pathway. This raises the risk of drug accumulation and toxicity even without any acute illness.
Which organ matters more for a given drug — liver or kidney?
It depends on the drug. Check whether the medication is primarily metabolised (liver) or excreted unchanged or as active metabolites (kidney), then look at the corresponding lab value — LFTs for hepatic clearance, creatinine and eGFR for renal clearance — before assuming a standard dose is still safe.
What's a red flag that a patient is accumulating a drug rather than responding normally to it?
A clinical picture that doesn't match the expected effect of the dose — new confusion, sedation, or bradycardia days into treatment with no dose change — alongside a rising creatinine or abnormal liver function tests. This combination should prompt a hold on the next dose and a call to the prescriber.
More on pharmacology
Guides on this